Expanding role of lipid II as a target for lantibiotics

Future Microbiology

Volumn 2, Issue 5, 2007, Pages 513-525

  Martin, Nathaniel I ^a   Breukink, Eefjan ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antibiotic; Lacticin 3147; Lantibiotic; Lantibiotic mode of action; Lipid II; Nisin; Peptidoglycan

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; DALBAVANCIN; EPIDERMIN; KATANOSIN; LACTICIN 3147 A1; LACTICIN 3147 A2; LANTIBIOTIC; LIPID; MANNOPEPTIMYCIN; MERSACIDIN; MONOBACTAM; NATURAL PRODUCT; NISIN; ORITAVANCIN; PENICILLIN DERIVATIVE; PLUSBACIN; POLYPEPTIDE ANTIBIOTIC AGENT; RAMOPLANIN; SUBTILIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERIAL GROWTH; CELL DESTRUCTION; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIOCINS; DRUG RESISTANCE, BACTERIAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; URIDINE DIPHOSPHATE N-ACETYLMURAMIC ACID; VANCOMYCIN;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 35348913834     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.5.513     Document Type: Review

References (102)

1. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL: Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
2. Harz H, Burgdorf K, Holtje JV. Isolation and separation of the glycan strands from murein of Escherichia coli by reversed-phase high-performance liquid chromatography. Anal. Biochem. 190, 120-128 (1990).
3. Lovering AL, de Castro LH, Lim D, Strynadka NC: Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. Science 315, 1402-1405 (2007).
4. Yuan Y, Barrett D, Zhang Y, Kahne D, Sliz P, Walker S: Crystal structure of a peptidoglycan glycosyltransferase suggests a model for processive glycan chain synthesis. Proc. Natl. Acad Sci. USA 104, 5348-5353 (2007).
5. Walsh C: In: Antibiotics. Actions, Origins, Resistance. ASM Press, Washington DC, USA (2003).
6. van Heijenoort J: Recent advances in the formation of the bacterial peptidoglycan monomer unit. Nat. Prod Rep. 18, 503-519 (2001).
7. Lazar K, Walker S: Substrate analogues to study cell-wall biosynthesis and its inhibition. Curr. Opin. Chem. Biol. 6, 786-793 (2002).
8. van Dam V, Sijbrandi R, Kol M, Swiezewska E, de Kruijff B, Breukink E: Transmembrane transport of peptidoglycan precursors across model and bacterial membranes. Mol Microbiol. 64, 1105-1114 (2007).
9. Labischinski H, Goodell EW, Goodell A, Hochberg ML: Direct proof of a 'more-than-single-layered' peptidoglycan architecture of Escherichia coli W7: a neutron small-angle scattering study. J Bacteriol. 173, 751-756 (1991).
10. Kramer NE, Smid EJ, Kok J, de Kruijff B, Kitipers OP, Breukirik E: Resistance of Gram-positive bacteria to nisin is not determined by lipid II levels. FEMS Microbiol Lett. 239, 157-161 (2004).
11. Stone K, Strominger JL: Binding of bacitracin to cells and protoplasts of Micrococcus lysodeikticus. J. Biol. Chem. 249, 1823-1827 (1974).
12. McCloskey MA, Troy FA: Paramagnetic isoprenoid carrier lipids. 1. Chemical synthesis and incorporation into model membranes. Biochemistry 19,2056-2060 (1980).
13. McCormick MH, McGuire JM, Pittenger GE, Pittenger RC, Stark WM: Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot. Annu. 3, 606-611 (1955).
14. Widboom PF, Fielding EN, Liu Y, Bruner SD: Structural basis for cofactor-independent dioxygenation in vancomycin biosynthesis. Nature 447, 342-345 (2007).
15. Zerbe Y, Woithe K, Li DB, Vitali F, Bigler L, Robinson JA: An oxidative phenol coupling reaction catalyzed by oxyB, a cytochrome P450 from the vancomycin-producing microorganism. Angew. Chem. Int. Ed Engl. 43, 6709-6713 (2004).
16. Woithe K, Geib N, Zerbe K et al.: Oxidative phenol coupling reactions catalyzed by OxyB: a cytochrome P450 from the vancomycin producing organism. Implications for vancomycin-biosynthesis. J. Am. Chem. Soc. 129, 6887-6895 (2007).
17. Williamson MP, Williams DH: Structure revision of the antibiotic vancomycin. Use of nuclear Overhauser effect difference spectroscopy. J. Am. Chem. Soc. 103, 6580-6585 (1981).
18. Sheldrick GM, Jones PG, Kennard O, Williams DH, Smith GA: Structure of vancomycin and its complex with acetyl-D-alanyl-D-alnine. Nature 271, 223-225 (1978).
19. Harris CM, Harris TM: Structure of the glycopeptide antibiotic vancomycin. Evidence for an asparagine residue in the peptide. J. Am. Chem. Soc. 104, 4293-4295 (1982).
20. Perkins HR. Specificity of combination between mucopetide precursors and vancomycin or ristocetin. Biochem. J. 111, 195-205 (1969).
21. Charterjee AN, Perkins HR. Compounds formed between nucleotides related to the biosynthesis of bacterial cell wall and vancomycin. Biochem. Biophys. Res. Commun. 24,489-494 (1966).
22. Molinari H, Pastore A, Lian LY, Hawkes GE, Sales K: Structure of vancomycin and a vancomycin/D-Ala-D-Ala complex in solution. Biochemistry 29, 2271-2277 (1990).
23. Vollmerhaus PJ, Breukink E, Heck AJ: Getting closer to the real bacterial cell wall target: biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics. Chemistry 9, 1556-1565 (2003).
24. Arthur M, Courvalin P: Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37, 1563-1571 (1993).
25. Appelbaum PC: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1), 16-23 (2006).
26. Appelbaum PC, Jacobs MR: Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol. 8, 510-517 (2005).
27. Johnson AP, Uttley AH, Woodford N, George RC: Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol. Rev. 3, 280-291 (1990).
28. Malabarba A, Goldstein BP: Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55(Suppl. 2) ii15-ii20 (2005).
29. Higgins DL, Chang R, Debabov DV et al.: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127-1134 (2005).
30. Mercier RC, Hrebickova L: Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev. Anti. Infect. Ther. 3, 325-332 (2005).
31. McCafferty DG, Cudic P, Frankel BA, Barkallah S, Kruger RG, Li W: Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 66, 261-284 (2002).
32. Walker S, Chen L, Hu Y, Rew Y, Shin D, Boger DL: Chemistry and biology of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity. Chem. Rev. 105, 449-476 (2005).
33. Helm JS, Chen L, Walker S: Rethinking ramoplanin: the role of substrate binding in inhibition of peptidoglycan biosynthesis. J. Am. Chem. Soc. 124, 13970-13971 (2002).
34. Singh MP, Petersen PJ, Weiss WJ et al.: Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities. Antimicrob. Agents Chemother. 47, 62-69 (2003).
35. Ruzin A, Singh G, Severin A et al.: Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 48, 728-738 (2004).
36. Shoji J, Hinoo H, Katayama T et al.: Isolation and characterization of new peptide antibiotics, plusbacins A1-A4 and B1-B4. J. Antibiot. (Tokyo) 45, 817-823 (1992).
37. Maki H, Miura K, Yamano Y: Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 1823-1827 (2001).
38. Shoji J, Hinoo H, Matsumoto K et al.: Isolation and characterization of katanosins A and B. J. Antibiot. (Tokyo) 41, 713-718 1988.
39. Breukink E, de Kruijff B: Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5, 321-332 (2006).
40. Twomey D, Ross RP, Ryan M, Meaney B, Hill C: Lantibiotics produced by lactic acid bacteria: structure, function and applications. Antonie Van Leeuwenhoek 82, 165-185 (2002).
41. McAuliffe O, Ross RP, Hill C: Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol. Rev. 25, 285-308 (2001).
42. Rogers LA: The inhibiting effect of Streptococcus lactis on Lactobacillus bulgaricus. J. Bacteriol. 16, 321-325 (1928).
43. Brumfitt W, Salton MR, Hamilton-Miller JM: Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrob. Chemother. 50, 731-734 (2002).
44. Severina E, Severin A, Tomasz A: Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J. Antimicrob. Chemother. 41, 341-347 (1998).
45. Mota-Meira M, LaPointe G, Lacroix C, Lavoie MC: MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against - bacterial pathogens. Antimicrob. Agents Chemother. 44, 24-29 (2000).
46. Stevens KA, Sheldon BW, Klapes NA, Klaenhammer TR: Nisin treatment for inactivation of Salmonella species and other Gram-negative bacteria. Appl. Environ. Microbiol. 57, 3613-3615 (1991).
47. Chatterjee S, Chatterjee DK, Jani RH et al.: Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J. Antibiot. (Tokyo) 45, 839-845 (1992).
48. Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A: Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54, 648-653 (2004).
49. Guder A, Wiedemann I, Sahl HG: Posttranlationally modified bacteriocins - the lantibiotics. Biopolymers 55, 62-73 (2000).
50. Jung G, Sahl HG: In: Nisin and Novel Lantibiotics. Escom Publishers, Leiden, The Netherlands (1991).
51. Chatterjee C, Paul M, Xie L, van der Donk WA: Biosynthesis and mode of action of lantibiotics. Chem. Rev. 105, 633-684 (2005).
52. Cotter, PD, Hill C, Ross RP: Bacterial lantibiotics: strategies to improve therapeutic potential. Curr. Protein Pept. Sci. 6, 61-75 (2005).
53. Schnell N, Entian KD, Schneider U et al.: Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature 333, 276-278 (1988).
54. Xie L, Miller LM, Chatterjee C, Averin O, Kelleher NI, van der Donk WA: Lacticin 481: in vitro reconstitution of lantibiotic synthetase activity. Science 303, 679-681 (2004).
55. Li B, Yu JP, Brunzelle JS, Moll GN, van der Donk WA, Nair SK: Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science 311, 1464-1467 (2006).
56. Rince A, Dufour A, Le Pogam S, Thuault D, Bourgeois CM, Le Pennec JP: Cloning, expression, and nucleotide sequence of genes involved in production of lactococcin DR, a bacteriocin from lactococcus lactis subsp. lactis. Appl. Environ. Microbiol. 60, 1652-1657 (1994).
57. Uguen P, Le Pennec JP, Dufour A: Lantibiotic biosynthesis: interactions between prelacticin 481 and its putative modification enzyme, LctM. J. Bacteriol. 182, 5262-5266 (2000).
58. Dufour A, Hindre T, Haras D, Le Pennec JP: The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol. Rev. 31, 134-167 (2007).
59. You YO, van der Donk WA: Mechanistic investigations of the dehydration reaction of lacticin 481 synthetase using site-directed mutagenesis. Biochemistry 46, 5991-6000 (2007).
60. Linnett PE, Strominger JL: Additional antibiotic inhibitors of peptidoglycan synthesis. Antimicrob. Agents Chemother. 4, 231-236 (1973).
61. Reisinger P, Seidel H, Tschesche H, Hammes WP: The effect of nisin on murein synthesis. Arch. Microbiol. 127, 187-193 (1980).
62. Ruhr E, Sahl HG: Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob. Agents Chemother. 27, 841-845 (1985).
63. Garcera MJ, Elferink MG, Driessen AJ, Konings WN: In vitro pore-forming activity of the lantibiotic nisin. Role of proton motive force and lipid composition. Eur. J. Biochem. 212, 417-422 (1993).
64. Breukink E, van Kraaij C, Demel RA, Siezen RJ, Kuipers OP, de Kruijff B: The C-terminal region of nisin is responsible for the initial interaction of nisin with the target membrane. Biochemistry 36, 6968-6976 (1997).
65. Breukink E, Ganz P, de Kruijff B, Seelig J: Binding of Nisin Z to bilayer vesicles as determined with isothermal titration calorimetry. Biochemistry 39, 10247-10254 (2000).
66. Martin I, Ruysschaert JM, Sanders D, Giffard CJ: Interaction of the lantibiotic nisin with membranes revealed by fluorescence quenching of an introduced tryptophan. Eur. J. Biochem. 239, 156-164 (1996).
67. Brotz H, Josten M, Wiedemann I et al.: Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30, 317-327 (1998).
68. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H, de Kruijff B: Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286, 2361-2364 (1999).
69. Breukink E, van Kraaij C, van Dalen A et al.: The orientation of nisin in membranes. Biochemistry 37, 8153-8162 (1998).
70. Sahl HG, Kordel M, Benz R: Voltage-dependent depolarization of bacterial membranes and artificial lipid bilayers by the peptide antibiotic nisin. Arch. Microbiol. 149, 120-124 (1987).
71. van Heusden HE, de Kruijff B, Breukink E: Lipid II induces a transmembrane orientation of the pore-forming peptide lantibiotic nisin. Biochemistry 41, 12171-12178 (2002).
72. Wiedemann I, Benz R, Sahl HG: Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. J. Bacteriol. 186, 3259-3261 (2004).
73. Breukink E, van Heusden HE, Vollmerhaus PJ et al.: Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J. Biol. Chem. 278, 19898-19903 (2003).
74. Bonev BB, Breukink E, Swiezewska E, De Kruijff B, Watts A: Targeting extracellular pyrophosphates underpins the high selectivity of nisin. FASEB J. 18, 1862-1869 (2004).
75. Hasper HE, de Kruijff B, Breukink E: Assembly and stability of nisin-lipid II pores. Biochemistry 43, 11567-11575 (2004).
76. Hsu ST, Breukink E, Tischenko E et al.: The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 11, 963-967 (2004).
77. Wiedemann I, Breukink E, van Kraaij C et al.: Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276, 1772-1779 (2001).
78. Bonelli RR, Schneider T, Sahl HG, Wiedemann I: Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies. Antimicrob. Agents Chemother. 50, 1449-1457 (2006).
79. Hasper HE, Kramer NE, Smith JL et al.: An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313, 1636-1637 (2006).
80. Brotz H, Bierbaum G, Leopold K, Reynolds PE, Sahl HG: The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 42, 154-160 (1998).
81. Hsu ST, Breukink E, Bierbaum G et al.: NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. J. Biol. Chem. 278, 13110-13117 (2003).
82. Garneau S, Martin NI, Vederas JC: Two-peptide bacteriocins produced by lactic acid bacteria. Biochimie 84, 577-592 (2002).
83. O'Connor EB, Cotter PD, O'Connor P et al.: Relatedness between the two-component lantibiotics lacticin 3147 and staphylococcin C55 based on structure, genetics and biological activity. BMC Microbiol. 7, 24 (2007).
84. Martin NI, Sprules T, Carpenter MR et al.: Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry 43, 3049-3056 (2004).
85. Cotter PD, Deegan LH, Lawton EM et al.: Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol. Microbiol. 62, 735-747 (2006).
86. Wiedemann I, Bottiger T, Bonelli R et al.: The mode of action of the lantibiotic lacticin 3147 - a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol. Microbiol. 61, 285-296 (2006).
87. Cox CR, Coburn PS, Gilmore MS: Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. Curr. Protein Pept. Sci. 6, 77-84 (2005).
88. Ryan MP, Jack RW, Josten M et al.: Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147. J. Biol. Chem. 274, 37544-37550 (1999).
89. Holo H, Jeknic Z, Daeschel M, Stevanovic S, Nes IF: Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiolgy 147, 643-651 (2001).
90. Navaratna MA, Sahl HG, Tagg JR: Two-component anti-Staphylococcus aureus lantibiotic activity produced by Staphylococcus aurerus C55. Appl. Environ. Microbiol. 64, 4803-4808 (1998).
91. Yonezawa H, Kuramitsu HK: Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob. Agents Chemother. 49, 541-548 (2005).
92. Hyink O, Balakrishnan M, Tagg JR: Streptococcus rattus strain BHT produces both a class I two-components lantibiotic and a class II bacteriocin. FEMS Microbiol. Lett. 252, 235-241 (2005).
93. McClerren AL, Cooper LE, Quan C, Thomas PM, Kelleher NL, van der Donk WA: Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc. Natl Acad. Sci. USA 103, 17243-17248 (2006).
94. Mantovani HC, Russell JB: Nisin resistance of Streptococcus bovis. Appl. Environ. Microbiol. 67, 808-813 (2001).
95. Breuer B, Radler F: Inducible resistance against nisin in Lactobacillus casei. Arch. Microbiology 165, 114 (1996).
96. Maisnier-Patin S, Richard J: Cell wall changes in nisin-resistant variants of Listeria innocua grown in the presence of high nisin concentrations. FEMS Microbiol. Lett. 140, 29-35 (1996).
97. Verheul A, Russell NJ, Van THR, Rombouts FM, Abee T: Modifications of membrane phospholipid composition in nisin-resistant Listeria monocytogenes Scott A. Appl. Environ. Microbiol. 63, 3451-3457 (1997).
98. Crandall AD, Montville TJ: Nisin resistance in Listeria monocytogenes ATCC 700302 is a complex phenotype. Appl Environ. Microbiol. 64, 231-237 (1998).
99. Davies EA, Falahee MB, Adams MR: Involvement of the cell envelope of Listeria monocytogenes in the acquisition of nisin resistance. J. Appl. Bacteriol. 81, 139-146 (1996).
100. Neuhaus FC, Baddiley J: A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in Gram-positive bacteria. Microbiol. Mol. Biol. Rev. 67, 686-723 (2003).
101. Kramer NE: Nisin resistance in Gram-positive bacteria. Utrecht University (2005).
102. Cao M, Helmann JD: The Bacillus subtilis extracytoplasmic-function sigmaX factor regulates modification of the cell envelope and resistance to cationic antimicrobial peptides. J. Bacteriol. 186, 1136-1146 (2004).